作者根据37篇国内外文献有关报道,介绍了血管紧张素转化酶特异性抑制剂甲巯丙脯酸(SQ14225)的药理作用、临床应用等方面的研究进展。经过国内初步临床验证,甲巯丙脯酸是口服有效的血管紧张素转化酶抑制剂,其降压作用是双重的,优于目前临床应用的肌丙抗增压素和壬肽抗压素。 Based on the 37 reports of domestic and foreign literature, the author introduced the research progress of the pharmacological action and clinical application of the captopril (SQ14225), a specific inhibitor of angiotensin converting enzyme. After preliminary clinical validation, captopril is an orally available and effective angiotensin converting enzyme inhibitor with a dual antihypertensive effect, which is superior to the current clinical application of antihypertension and nonylpeptide.